

## **Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition**

Yu-Chen Lee<sup>1</sup>, Song-Chang Lin<sup>1</sup>, Guoyu Yu<sup>1</sup>, Ming Zhu<sup>2</sup>, Jian H Song<sup>2</sup>, Keith Rivera<sup>3</sup>, Darryl Pappin<sup>3</sup>, Christopher J. Logothetis<sup>2</sup>, Theocharis Panaretakis<sup>2</sup>, Guocan Wang<sup>2</sup>, Li-Yuan Yu-Lee<sup>4</sup>, Sue-Hwa Lin<sup>1,2</sup>

Departments of <sup>1</sup>Translational Molecular Pathology, <sup>2</sup>Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA; <sup>3</sup>Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA; <sup>4</sup>Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.

**Running title:** Tenascin C from EC-to-OSB transition promotes PCa bone metastasis

**Key words:** prostate cancer, bone metastasis, EC-to-OSB transition, iTRAQ, Tenascin C

**Correspondence:** Sue-Hwa Lin, Department of Translational Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. Phone: 713-794-1559; Fax: 713-834-6084; E-mail: [slin@mdanderson.org](mailto:slin@mdanderson.org)

**Conflict of interest:** C. J. Logothetis reports receiving commercial research grants from Bayer, Sanofi, Janssen, Astellas Pharma, Pfizer; and honoraria from Bayer, Janssen, Sanofi, Astellas Pharma. No potential conflicts of interest were disclosed by the other authors.

## Abstract

Metastatic prostate cancer (PCa) in bone induces bone-forming lesions that enhance PCa progression. How tumor-induced bone formation enhances PCa progression is not known. We have previously shown that PCa-induced bone originates from endothelial cells (EC) that have undergone endothelial-to-osteoblast (EC-to-OSB) transition by tumor-secreted BMP4. Here, we show that EC-to-OSB transition leads to changes in the tumor microenvironment that increases the metastatic potential of PCa cells. We found that conditioned medium (CM) from EC-OSB hybrid cells increases the migration, invasion and survival of PC3-mm2 and C4-2B4 PCa cells. Quantitative mass spectrometry (iTRAQ) identified Tenascin C (TNC) as one of the major proteins secreted from EC-OSB hybrid cells. TNC expression in tumor-induced osteoblasts was confirmed by immunohistochemistry of MDA-PCa118b xenograft and human bone metastasis specimens. Mechanistically, BMP4 increases TNC expression in EC-OSB cells through the Smad1-Notch/Hey1 pathway. How TNC promotes PCa metastasis was next interrogated by in vitro and in vivo studies. In vitro studies showed that a TNC neutralizing antibody inhibits EC-OSB-CM-mediated PCa cell migration and survival. TNC knockdown decreased, while addition of recombinant TNC or TNC overexpression increased migration and anchorage-independent growth of PC3 or C4-2b cells. When injected orthotopically, PC3-mm2-shTNC clones decreased metastasis to bone, while C4-2b-TNC overexpressing cells increased metastasis to lymph nodes. TNC enhances PCa cell migration through  $\alpha 5\beta 1$  integrin-mediated YAP/TAZ inhibition. These studies elucidate that tumor-induced stromal reprogramming generates TNC that enhances PCa metastasis and suggest that TNC may be a target for PCa therapy.

## Introduction

Lethal prostate cancer (PCa) is dominated by complications arising from bone metastasis. One unique feature of PCa bone metastasis is the induction of aberrant bone formation [1, 2]. This contrasts with other cancers, e.g., renal carcinoma and multiple myeloma, which induce osteolytic bone lesions. We and others have shown that PCa-induced aberrant bone formation is partly due to PCa-secreted bone morphogenetic protein (BMP) family proteins, including BMP4 [3] and BMP6 [4], which increase osteoblast differentiation. Such a stromal reprogramming by PCa was shown to enhance PCa progression in bone [3, 5]. However, how tumor-induced bone enhances PCa progression is not known.

Elucidating mechanisms by which PCa induces aberrant bone formation will allow us to identify factors that are involved in such a pathological event. Tumors are known to recruit cells, e.g., endothelial cells, from the host microenvironment to support their growth. Using an osteogenic patient-derived xenograft (PDX) MDA PCa-118b, we found that prostate tumors recruited host (mouse) stromal cells and converted them into osteoblasts (OSB) [5]. We further showed that BMP4 induces tumor associated-endothelial cells (ECs) to undergo endothelial-to-osteoblast (EC-to-OSB) transition, resulting in ectopic bone formation [5]. During BMP4-mediated EC-to-OSB transition, Tie2<sup>+</sup> ECs undergo transition to become osteocalcin<sup>+</sup> (Ocl<sup>+</sup>) OSBs, generating EC-OSB hybrid cells that express both Tie2 and Ocl [5]. EC-OSB hybrid cells were found to form a rim along tumor-induced bone and are located in close proximity with tumor cells [5]. We recapitulated the bone forming process in vitro by showing that EC-OSB hybrid cells can further differentiate into mature OSBs when cultured in OSB differentiation medium [5].

The signaling pathways mediating EC-to-OSB transition was examined using an EC line 2H11 [6]. We found that multiple pathways, including Smad1-Notch/Hey1, GSK3β-βcatenin-Slug, and Smad1-Dlx2 pathways are involved in BMP4-mediated EC-to-OSB transition. Activation of these pathways results in upregulation of several transcription factors, including Osx, Dlx2, Slug and Hey1, which play critical roles in EC transition into OSB, OSB differentiation, and bone matrix mineralization [6]. Together, these findings uncovered the mechanism of PCa-induced aberrant bone formation.

The mechanistic understanding of PCa-induced aberrant bone formation allows us to address how tumor-induced bone enhances PCa progression. Because EC-OSB hybrid cells generated during EC-to-OSB transition are a unique cell type before they become mature

osteoblasts [5], factors that are secreted by EC-OSB hybrid cells may elicit paracrine effects on tumor cells to modulate their properties. In this study, we identified factors secreted from EC-OSB hybrid cells and found Tenascin C, an extracellular matrix glycoprotein, to be one of the major factors. Using in vitro and in vivo approaches, we showed that Tenascin C increases the metastatic potential of PCa cells, providing a mechanism by which PCa-mediated stromal cell reprogramming enhances PCa progression in bone.

## Results

### **Conditioned media from EC-OSB hybrid cells increase the migration, invasion and anchorage-independent growth of prostate cancer cells**

We previously showed that treatment of 2H11 endothelial cells (EC) with BMP4 (100 ng/ml) for 48 h leads EC to transition into osteoblasts (OSB). During EC-to-OSB transition, cells underwent a change in cell morphology, from a cuboidal shape to a more elongated shape (Fig. 1A), that was accompanied by a significant increase in the expression of OSB markers alkaline phosphatase and osteocalcin (Fig. 1B). We designated the cells that are undergoing transition as EC-OSB hybrid cells, and examined whether conditioned media (CM) from EC-OSB hybrid cells can modulate PCa cell activities (Fig. 1C). EC-OSB-CM was found to significantly increase the migratory (Fig. 1C) and invasive (Fig. 1D) activities of C4-2B4 and PC3-mm2 PCa cells relative to control 2H11-CM. EC-OSB-CM was also found to significantly increase tumor cell survival in anchorage-independent growth in soft agar assay relative to control 2H11-CM (Fig. 1E), without having an effect on PCa cell proliferation (Supplementary Fig. 1A, B). Further, adding BMP4 directly to PCa cells as a control did not have effects on these activities (Fig. 1C – E). These results suggest that EC-OSB hybrid cells secrete factors that stimulate the migration, invasion and anchorage-independent growth of PCa cells (Fig. 1F).

### **iTRAQ analysis identifies Tenascin C in EC-OSB-CM**

We employed Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) to compare the levels of proteins in EC-OSB-CM versus 2H11-CM (Fig. 2A) in triplicate samples. A total of 1414 proteins with p values of less than 0.017, corresponding to a 1% false discovery rate in Mascot search, were identified. Based on the iTRAQ ratio between two samples, 133 proteins

were found to be upregulated (with changes in protein ratios of >1.22-fold) and 663 proteins downregulated (with changes <0.81-fold) in EC-OSB-CM versus control 2H11-CM (Supplementary Table 1). The numbers for significance (1.22 and 0.81) were calculated by taking all the numbers in the BMP4 average column and using the Easyfit program to find the distribution that best fit the data. From this we calculated a 2-sigma up/down number for the whole distribution. The top 15 proteins with the highest fold change were extracellular matrix proteins, including Tenascin C (TNC), CTGF, Versican and other secreted factors (Fig. 2B). TNC and TNC isoform 2 are the most promising candidate proteins due to a high number of significant peptides, 174 and 172 peptides, respectively, identified for isoform 1 and 2, respectively (Supplementary Table 1). Mouse TNC is a secreted protein of 2110 amino acids, containing 15 EGF-like domains in N-terminus (aa 174-621), 14 fibronectin type III domains (aa 625-1886), and a C-terminus fibrinogen domain. TNC isoform 2 differs from TNC in its absence of domain #10 of fibronectin type III domain (aa 1436-1526), resulting in a protein of 2019 amino acids, which is about 10 kDa less in molecular weight than TNC. Based on the comparable numbers of peptides identified in mass spectrometry during iTRAQ analysis, the levels of TNC and TNC isoform 2 secreted from 2H11 cells during BMP4 stimulation are predicted to be similar.

Real-time RT-PCR confirmed the significant upregulation of TNC, Versican and CTGF mRNAs in BMP4-treated 2H11 cells (Fig. 2C). TNC also showed the highest abundance in mRNA levels, around 5-fold higher compared to those of Versican and CTGF, based on mRNA to GAPDH ratio (Fig. 2C). Because TNC was the most upregulated and abundantly-expressed protein, we selected TNC for further study. TNC is a large extracellular matrix protein with an apparent molecular mass of ~250 kDa [7], which may correspond to the elevated 250 kDa protein band seen on SDS-PAGE of EC-OSB CM (Supplementary Fig. 1C, arrow). TNC protein was upregulated not only in the cell pellet of EC-OSB hybrid cells compared to 2H11 cells (Fig. 2D) but also accumulated in EC-OSB-CM from 48 to 72 h (Fig. 2E). Elevated expression of TNC was also observed in EC-OSB hybrid cells by immunofluorescence relative to control 2H11 cells (Fig. 2F).

BMP4-induced EC-to-OSB transition occurs in several stages [5]. Upon BMP4 treatment, 2H11 cells transition into OSB by day 3 in serum-free medium (SF) (Days 0-3, Transition Phase). EC-OSB hybrid cells then undergo OSB differentiation in differentiation

medium and express bone matrix proteins (Days 3-10, Differentiation Phase), and finally mineralized by Day 20 (Mineralization Phase) (Fig. 2G, upper). Consistently, the osteogenesis marker alkaline phosphatase showed a time-dependent increase of enzyme activity during the Differentiation and Mineralization Phases (Fig. 2G, lower left). qRT-PCR of BMP4-treated 2H11 cells (Fig. 2G, lower middle) and Western blot of the corresponding CM (Fig. 2G, lower right) showed that TNC was highly upregulated during the Transition Phase. Note, depending on the gel running condition, TNC may appear as a broad single band or be resolved into a 250 kDa TNC doublet of distinct bands in western blot analysis. These results suggest that TNC is mainly expressed during the early phase of EC-to-OSB transition.

### **Tenascin C is expressed in tumor-induced osteoblasts in PDX and human bone metastasis specimens**

We examined whether TNC is induced in the EC-OSB hybrid cells of osteogenic tumors by immunohistochemical analysis. In the osteogenic MDA PCa-118b xenograft tumors, which is a PDX generated from the osteoblastic bone lesions of a patient with bone metastasis [8], TNC is highly expressed in tumor-induced OSBs (Fig. 3A). Similarly, in another osteogenic tumor model in which BMP4 was overexpressed in C4-2b cells [5], TNC is also expressed in the OSBs rimming the tumor-induced bone in the C4-2b-BMP4 tumors (Supplementary Fig. 2A). Further, we observed that TNC is mainly localized in the tumor-induced bone matrix that surrounds the metastatic PCa cells in human bone metastasis specimens (Fig. 3A and Supplementary Fig. 2B-C).

### **Tenascin C neutralizing antibody reduces migration stimulatory activity of EC-OSB-CM**

Next, we incubated EC-OSB-CM with monoclonal antibody BC-24 [9], a TNC neutralizing antibody that recognizes the N-terminal epidermal growth factor-like sequence that is present in both TNC and TNC isoform 2. Antibody AE1/AE3 that recognizes cytokeratins was used as a control. Treatment with BC-24 antibody, but not control antibody, abrogated the migration stimulating activity (Fig. 3B) as well as anchorage-independent growth stimulating activity (Fig. 3C) in EC-OSB-CM for both C4-2B4 and PC3-mm2 cells. These results suggest that EC-OSB hybrid cells secrete TNC that promotes PCa migration, invasion and anchorage-independent growth (Fig. 3D).

### **BMP4 increases Tenascin C in EC-OSB hybrid cells through Smad1-Notch/Hey1 pathway**

Next, we examined the mechanism by which BMP4 increases TNC expression. We found that inhibition of BMP receptor kinase activity with 100 nM LDN193189 decreased BMP4-mediated phosphorylation of Smad1 and TNC protein levels in the CM (Fig. 4A). Although both Smad1 and Smad5 can be phosphorylated by BMP4 stimulation, Smad1 is expressed at a high level while Smad5 is low to undetectable in 2H11 cells (Supplementary Fig. 2D). Incubation of 2H11 cells with LDN alone did not have an impact on total Smad1 levels as they were comparable to those in control cells (Fig. 4A). Knockdown of Smad1 in 2H11 cells by shRNA in 2H11-shSmad1#1, #3, and #5 clones (Supplementary Fig. 2D) significantly reduced BMP4-stimulated pSmad1 (Fig. 4B) and led to a significant reduction in BMP4-stimulated TNC expression at both the TNC mRNA and TNC protein levels in the corresponding CM (Fig. 4C). These results suggest that TNC expression in 2H11 cells is mediated through BMP4-activated Smad1 signaling.

We previously showed that pSmad1 forms a complex with Notch intracellular domain (NICD) to upregulate Hey1, one of the most highly-expressed transcription factors during EC-to-OSB transition [6]. LDN193189 treatment abrogated BMP4-induced Hey1 mRNA expression (Fig. 4D), consistent with a role of pSmad1 in Hey1 regulation. Knockdown of Hey1 in 2H11-shHey1#2 and #5 clones (Fig. 4E) significantly reduced BMP4-stimulated TNC expression at both the mRNA and protein levels (Fig. 4F). These results suggest that upregulation of Hey1 is necessary for BMP4-mediated TNC expression. Next, we overexpressed Hey1 in 2H11 cells (oeHey1) (Fig. 4G) and showed that TNC mRNA and protein levels were significantly increased in 2H11-oeHey1 cells compared to control vector-transfected cells (Fig. 4H). These results suggest that Hey1 is necessary and sufficient for TNC expression in 2H11 cells. Co-transfection of a TNC promoter-luciferase construct together with an Hey1 expression vector into 293T cells resulted in a significant increase in TNC promoter activity only in the presence of Hey1 (Fig. 4I), suggesting that Hey1 has a direct effect on TNC expression in 2H11 cells. These results support that BMP4-induced TNC expression during EC-to-OSB transition is largely mediated through a pSmad1-Notch/Hey1 signaling pathway (Fig. 4J).

### **Tenascin C is expressed in prostate cancer cells with high metastatic potential**

Although TNC is mainly secreted by stromal EC-OSB hybrid cells, TNC is also reported to be expressed in highly metastatic breast cancer cells [10], possibly due to epithelial-to-mesenchymal transition. We found that the highly metastatic PCa cells, i.e., PC3, PC3-mm2 and DU145 cells, express high levels of TNC mRNA (Fig. 5A, upper) and secrete high levels of TNC in their CMs (Fig. 5A, lower). The less aggressive PCa cells, i.e., LNCaP, C4-2B, C4-2B4, 22RV1 and VCaP cells, express low levels of TNC (Fig. 5A and Supplementary Fig. 9A-B). Interestingly, as also observed in EC-OSB conditioned media (Fig. 2 and 4), TNC and TNC isoform 2 appeared in concert in the 250 kDa TNC doublet, and their levels were similarly altered in the various PCa cells (Fig. 5A).

### **Knockdown of Tenascin C decreases the migration, invasion and anchorage-independent growth of PC3-mm2 cells in vitro**

Next, we employed shRNA to knockdown TNC in PC3-mm2 cells. In PC3-shTNC#2, #5, #7 and #8 clones, TNC levels were reduced at the mRNA (Fig. 5B, left) and protein levels in the corresponding CM by western blot (Fig. 5B, middle) and ELISA (Fig. 5B, right). Knockdown of TNC in these PC3-shTNC clones was found to significantly decrease migration, invasion, and anchorage-independent growth (Fig. 5C and Supplementary Fig. 3A-C) relative to the vector control PC3-mm2 cells. Similarly, knockdown of TNC in C4-2b cells decreased migration, invasion and anchorage-independent growth but not proliferation of C4-2b-shTNC clones (Supplementary Fig. 4A-E).

### **Knockdown of Tenascin C reduces the metastasis of PC3-mm2 cells to bone in vivo**

To examine whether knockdown of TNC in PC3-mm2 cells has an impact on the metastasis of PC3-mm2 cells to bone, PC3-vector, PC3-shTNC#2, #5, or #8 cells were injected orthotopically into the mouse prostate (Fig. 5D). We found that knockdown of TNC had little effect on tumor growth in the prostate as monitored by bioluminescence (Fig. 5E). Because the number of tumor cells that metastasized to bone were too low to be detected by bioluminescence, we quantified the tumor cells that have metastasized to bone using human-specific *Alu*-qPCR [11]. We first established an *Alu* PCR standard curve by using DNA from PC3-mm2 cells. Then, we compared the *Alu* PCR signals obtained from each femur against the *Alu* standard curve to determine the number of PC3-mm2 cells present in each femur. We found that

knockdown of TNC in PC3-mm2 cells decreased the number of PC3-shTNC cells that metastasized from the prostate to bone compared to vector-transfected control cells (Fig. 5F, left). We detected tumor cells in 5 of 8 legs analyzed in vector control mice, 2 of 8 legs in PC3-shTNC#2, 0 of 6 legs in PC3-shTNC#5, and 1 of 10 legs in PC3-shTNC#8 mice (Fig. 5F, right). These results suggest that TNC increases the metastasis of PC3-mm2 from the prostate to the bone. Similar results were obtained when the experiment was repeated in a separate group of mice (Supplementary Fig. 3D-H). Together, these results suggest that TNC plays a role in the metastatic potential of PC3-mm2 cells.

### **Tenascin C increases the migration and anchorage-independent growth of C4-2B4 and PC3 cells in vitro**

Next, we examined whether TNC is sufficient to increase the metastatic potential of PCa cells. We examined the effects of TNC on C4-2B4 cells by incubation with recombinant human TNC, containing amino acid Gly23-Pro623 (the EGF-like domains) [12]. The addition of TNC led to a significant increase in the migration (Fig. 6A) and anchorage-independent growth (Fig. 6B) of C4-2B4 cells compared to medium only or BSA control. We next expressed the first 625 amino acids of TNC in C4-2b cells (C4-2b-TNC), and showed that the exogenously expressed TNC was detected at both the mRNA and protein levels (Fig. 6C). C4-2b-TNC cells exhibited a significant increase in migration, invasion and anchorage-independent growth compared to C4-2b-vector control cells (Fig. 6D – F). Overexpression of TNC had no effect on C4-2b-TNC cell proliferation in vitro compared to C4-2b-vector cells (Supplementary Fig. 5A). Similarly, overexpression of TNC in PC3 cells increased migration, invasion and anchorage-independent growth, but not cell proliferation in PC3-TNC cells (Supplementary Fig. 6A-E). These results suggest that TNC confers migratory and survival properties to both C4-2B4 and C4-2b PCa cells, which are sublines derived from LNCaP cells [13-16], as well as to PC3 cells.

### **Tenascin C increases the metastasis of C4-2b cells to lymph nodes in vivo**

To examine whether overexpression of TNC in C4-2b cells has an impact on the metastasis of C4-2b cells, C4-2b-vector and C4-2b-TNC cells were injected orthotopically into the prostate of intact mouse (Fig. 6G). Because C4-2b is a cell line with low metastasis potential [16], we examined the effect of TNC on the metastasis of C4-2b from prostate to lymph nodes.

Although tumors were inoculated in 10 mice each, 2 large and 1 small tumors were detected in C4-2b-vector and 3 large and 1 small tumors were detected in C4-2b-TNC injected mice. There was no significant difference in C4-2b-TNC tumor growth in the prostate compared to C4-2b-vector as measured by bioluminescence imaging and tumor weight (Supplementary Fig. 5B-E). After removing the tumors, the number of lymph node metastases from the three tumors from C4-2b-vector and four tumors from C4-2b-TNC were compared. We found that overexpression of TNC in C4-2b cells led to an increase in the number of lymph node metastasis compared to vector-transfected cells (Fig. 6G, Supplementary Fig. 5F). These results suggest that TNC increases the metastasis of C4-2b cells from prostate to lymph nodes. Together, these results support that EC-to-OSB transition generates a tumor microenvironment enriched with TNC that enhances metastatic progression of PCa (Fig. 6H).

### **Tenascin C promotes prostate cancer cell migration through $\alpha 5\beta 1$ -YAP/TAZ pathway**

Next, we examined the mechanism by which TNC promotes PCa cell migration. TNC signals through integrins, including  $\alpha 2\beta 1$  [17],  $\alpha 5\beta 1$  [18],  $\alpha 8\beta 1$  [19],  $\alpha 9\beta 1$  [20, 21], and  $\alpha v$  [22-24]. Using human integrin primers, we found that the mRNA levels of  $\alpha 5$ ,  $\alpha 11$ ,  $\alpha v$ ,  $\beta 1$ , and  $\beta 5$  are expressed at higher levels than other integrins in C4-2b cells (Fig. 7A). We then performed qRT-PCR for the mRNA levels of those candidate TNC receptors in C4-2b-vector and C4-2b-TNC cells. Interestingly, expression of TNC in C4-2b cells led to a decrease in the mRNA levels of  $\alpha 5$  and  $\beta 1$  (Fig. 7B), suggesting that  $\alpha 5$  and  $\beta 1$  may be the major integrins for TNC in C4-2b cells. Indeed, when C4-2b-TNC cells were treated with integrin  $\alpha 5\beta 1$  neutralizing antibody (Volociximab), we found that blocking integrin  $\alpha 5\beta 1$  significantly decreased TNC-mediated migration (Fig. 7C).

Various mechanisms have been reported for the effect of TNC on cell migration, including YAP inhibition [21], Src activation and FAK phosphorylation [22], and activation of Notch and Wnt signaling [10, 17]. Among these possible mechanisms, we found that YAP/TAZ inhibition is involved in TNC-mediated cell migration as follows. Exogenous expression of TNC in C4-2b cells led to a decrease in the levels of nuclear YAP1 protein (Fig. 7D). Interestingly, treatment of C4-2b cells with recombinant TNC also led to a decrease in YAP/TAZ-responsive promoter activity (Fig. 7E). Consistent with lowered nuclear YAP1 levels in C4-2b-TNC cells, there was a significant decrease in the expression of several YAP/TAZ target genes, including CTGF,

CYR61, and COL8A (Fig. 7F), thus supporting that TNC downregulates YAP1 nuclear levels and its activity in the nucleus. Knockdown of YAP1 in C4-2b cells by shRNA led to an increase in cell migration in C4-2b-shYAP1-265 and C4-2b-shYAP1-325 clones (Fig. 7G). Treatment of C4-2b-shYAP1 cells with recombinant TNC did not increase migration relative to BSA (Fig. 7H), suggesting that TNC-mediated migration is through YAP1. Furthermore, when C4-2b-TNC cells were incubated with anti- $\alpha 5\beta 1$  neutralizing antibody, the inhibitory effects of TNC on CTGF, CYR61, and COL8A expression were de-repressed (Fig. 7I). Similar studies were performed in PC3 cells. We found that  $\alpha 5\beta 1$  integrins are also expressed in PC3 cells (Supplementary Fig. 7A). We examined whether  $\alpha 5\beta 1$  also plays a role in TNC-mediated YAP1 regulation by treating PC3 cells with  $\alpha 5\beta 1$  neutralizing antibody. We found that  $\alpha 5\beta 1$  neutralizing antibody blocked TNC-mediated migration (Supplementary Fig. 7B) and increased the expression of YAP/TAZ target genes CTGF, CYR61 and COL8A in PC3 cells (Supplementary Fig. 7C). Knockdown of YAP1 in PC3 cells led to a significant increase in cell migration (Supplementary Fig. 7D) and abrogated TNC's effect on cell migration in the PC3-shYAP1 clones (Supplementary Fig. 7E). Together, these results suggest that TNC promotes PCa cell migration, at least in part, through integrin  $\alpha 5\beta 1$ -YAP/TAZ pathway (Fig. 7J).

## Discussion

We have identified a novel mechanism whereby PCa-induced EC-to-OSB transition leads to changes in the extracellular milieu that enhances the metastatic potential of PCa (Fig. 7J). We showed that BMP4-mediated Smad1-Notch/Hey1 signaling pathway leads to TNC secretion from 2H11 endothelial cells. TNC in turn enhances PCa cell migration through  $\alpha 5\beta 1$  integrin-mediated inhibition of the YAP1 pathway. These insights into stromal reprogramming-mediated metastatic progression may provide strategies to improve therapies for bone metastasis.

Previous studies by Sung et al. [25] showed that prostate stromal fibroblasts co-evolve with cancer cells through reciprocal cancer-stroma interaction in an in vitro co-culture system, suggesting that tumor-stromal interaction is a dynamic process. Recently, tumor-induced stromal reprogramming was shown to occur in many different cancer types, including pancreatic [26], liver [27], breast cancers [28], and tumor draining lymph nodes [29]. Tumor cells were also found to reprogram their immune microenvironment [30]. Knowledge of such tumor-

induced stromal changes will lead to therapies targeting the altered stromal components to improve therapy outcomes.

In this study, we used BMP4 to stimulate EC-to-OSB transition. While BMP6 [4] and BMP7 [31] were also shown to contribute to the bone-forming phenotype of PCa bone metastasis, we focused on BMP4 for the following reasons. First, we identified BMP4 as a factor that is secreted by the osteoblastic PDX MDA PCa 118b, and showed that BMP4 promotes tumor growth through osteogenesis [3]. Second, we validated this observation in humans, demonstrating high BMP4 expression in bone metastases but not primary tumors [5]. Third, Nordstand et al. [32] showed that BMP4 expression in human PCa bone metastases correlated with increased bone formation. It is likely that other BMP family proteins may also stimulate EC-to-OSB transition.

Our mechanistic studies revealed that BMP4 induced TNC expression during EC-to-OSB transition is mediated through the Smad1-Hey1 pathway. Although Hey1 transfection in HEK293 cells increases Tnc promoter activity, Hey1 may not directly bind and regulate expression of TNC as TNC promoter does not contain a Hey1 binding site and Hey1 is a transcriptional repressor [33]. TNC promoter is reported to contain GATA4 or GATA6 binding sites and Hey1 has been shown to interact with GATA6 [33]. Thus, it is possible that Hey1 increases TNC promoter activity through interaction with GATA6. The precise mechanism remains to be determined.

Previous studies in human GBM cells by Miroshnikova et al. [34] have shown that HIF1 $\alpha$  binds directly to a putative hypoxia-response element in the TNC promoter, resulting in increased expression of TNC that increases ECM stiffness and mechanosignalling. HIF1 $\alpha$  is also known to activate the Notch pathway [35]. Under hypoxic conditions, HIF1 $\alpha$  is recruited to the Notch-responsive promoter through binding with Notch intracellular domain [36]. Interestingly, Notch signaling is also shown to affect the hypoxic response via regulation of HIF2 $\alpha$  [37]. However, in our recent RNAseq analysis of BMP4 treated 2H11 cells during EC-to-OSB transition [6], we did not find upregulation of HIF1 $\alpha$  or HIF2 $\alpha$  during this process. Thus, the HIF1 pathway is not involved in the regulation of TNC expression during EC-to-OSB transition.

TNC has been shown to be an organ-specific driver of breast cancer metastasis. Oskarsson et al. [10] showed that TNC initiates and sustains lung colonization of breast tumor

cells. They also showed that TNC knockdown does not hinder mammary tumor growth but rather restricts the progression of lung micro-metastases [10]. We also found that TNC does not affect PCa proliferation but endows PCa cells with migratory and survival ability in vitro and increases their metastasis to lymph nodes and bone in vivo. In support of our observation, San Martin et al. [20] showed that TNC enhances PCa cell migration towards bone tissues in vitro. TNC is upregulated in reactive stroma in primary PCa [38] and is also shown to correlate with PCa progression [39]. Together, these observations strongly support a role of stromal TNC in PCa progression.

We found that TNC signals through  $\alpha 5\beta 1$  integrins in C4-2b and PC3 PCa cells. Integrins are composed of a large family of 18  $\alpha$  subunits and 8  $\beta$  subunits, which are able to generate 24 different integrins [40]. Integrins are widely expressed in many different cell types with various subunit combinations. The regulation of the expression of various integrin subunits in different cells are unknown. In previous studies, we found that C4-2B4, PC3-mm2 and MDA PCa-118b xenografts have different integrin expression profiles [41]. In our current studies, we found that the expression of integrins in C4-2B and PC3 cells are also somewhat different from those reported for C4-2B4 and PC3-mm2 cells, respectively. TNC has been shown to signal through various integrins, including  $\alpha 2\beta 1$  [17],  $\alpha 5\beta 1$  [18],  $\alpha 8\beta 1$  [19],  $\alpha 9\beta 1$  [20, 21], and  $\alpha v$  [22-24]. In studies by San Martin et al. [20], TNC was shown to signal through  $\alpha 9\beta 1$  integrin, which is expressed in VCaP but not LNCaP, C4-2b, PC3 or 22RV1 cells. Thus, it is likely that TNC may signal through different integrins expressed in different PCa cells. Because PCa is heterogeneous, the integrins expressed in human bone metastasis specimens may be different in different PCa patients and remain to be determined.

Our studies showed that TNC promotes cell migration through inhibition of YAP/TAZ signaling pathway. YAP/TAZ are known as the nuclear transducers of the Hippo pathway during development [42]. Interestingly, Dupont et al. [43] showed that YAP/TAZ has a unique role as nuclear relays of mechanical signals from cellular microenvironment, acting independently from the Hippo/LATS cascade [43]. Cells respond to soft matrices or reduce cell spreading by inhibiting YAP/TAZ activity [43]. We found that TNC inhibits YAP/TAZ activity, providing a mechanism by which TNC enhances cancer metastasis. How signaling information generated by TNC reduces YAP/TAZ activity is not clear. YAP/TAZ activities are regulated by multiple mechanisms [44]. Recently, it was reported that post-translational modification of

YAP1 by proline hydroxylation also plays a role in YAP/TAZ activity in PCa cells [45]. Whether TNC-mediated inhibition of YAP/TAZ activity is through proline hydroxylation is unknown. The signal transduction pathway linking TNC/integrin-mediated signaling to YAP/TAZ inhibition requires further investigation. Although TNC has been shown to increase FAK and Src phosphorylation in breast cancer cells [22], we did not find a consistent regulation of FAK and Src phosphorylation by TNC in PCa cells. Our results showed that overexpression of TNC in C4-2b cells did not increase levels of pY397-FAK and pY416-Src (Supplementary Fig. 8A), although downregulation of TNC in PC3 cells showed a trend of decrease in FAK and Src phosphorylation (Supplementary Fig. 8B). Thus, TNC likely uses different signaling pathways in different tumor cells to regulate cellular activity.

Because androgen receptor (AR) plays a critical role in PCa, it is interesting to consider whether AR has an impact on TNC levels in PCa cells. We found that TNC levels of AR-negative PC3 and PC3-mm2 cells were higher as compared to those in AR-expressing LNCaP, C4-2b, 22RV1 and VCAP cells (Supplementary Fig. 9). However, the TNC levels in another AR-negative line DU145 were found to be similar to those in AR-expressing C4-2b and C4-2B4 cells (Supplementary Fig. 9B). We then examined whether TNC expression correlated with levels of the AR V7 splice variant in these cells. A high level of AR V7 was detected in 22RV1 cells, followed by lower levels in VCaP cells, and low to undetectable levels in LNCaP, C4-2b and C4-2B4 cells (Supplementary Fig. 9B). Notably, we found that a similarly low level of TNC was found in 22RV1 (high AR V7) versus LNCaP (undetectable AR V7) cells (Supplementary Fig. 9B). Thus, neither AR nor AR V7 levels appear to impact TNC levels in PCa cells.

That tumor cells are able to modify tissue stroma to further promote their malignant progression suggests that targeting the tumor-induced changes in the tumor microenvironment should be included as an integral part of treatment strategies. TNC is downregulated in adult tissues but is re-expressed in tumors and the surrounding microenvironment [46], and TNC re-expression has been postulated to contribute to the acquisition of a migratory or stem cell-like phenotype by tumor cells [47]. As mice with TNC knockout develop normally [48], it is possible to consider using TNC neutralizing antibody for metastasis prevention. Another possibility is to use BMP receptor kinase inhibitor to inhibit EC-to-OSB transition. Several BMP receptor kinase inhibitors have been developed for skeletal related disease [49]. Our findings raise the interesting possibility of applying BMP receptor inhibitors for PCa bone

metastasis treatments. Together, our studies on the molecular mechanisms leading to the metastatic progression of PCa in bone open up the possibility for future development of strategies to prevent and treat bone metastases more effectively.

## **Materials and Methods**

### **Cell lines, antibodies and reagents**

Cell lines, antibodies and reagents are as listed (Supplementary Table 2). C4-2B4-LT (Luciferase-Tomato), C4-2b-LT and PC3-mm2-LT cells were generated previously [50]. Cell lines were authenticated using short tandem repeat (STR) profiling and regularly tested for mycoplasma.

### **Differentiation of 2H11 cells to EC-OSB hybrid cells**

2H11 cells were incubated overnight in serum-free media and treated with BMP4 (100 ng/mL) for 48-72 h to generate EC-OSB hybrid cells. For differentiation and mineralization, EC-OSB cells were further cultured in StemPro osteoblast differentiation medium (Gibco™) for 21 days. Alkaline phosphatase activity was measured in cell lysates using alkaline phosphatase kit.

### **Real-time RT-PCR**

Total RNA was isolated using Qiagen RNAeasy kit. 20 ng cDNA was used for qRT-PCR with primers as listed (Supplementary Table 3). Human integrin primers (HINT-1) were purchased from RealTimePrimers. C4-2b-TNC cells were starved overnight, treated with 150 µg/mL integrin  $\alpha 5\beta 1$  antibody or control IgG for 48 h before RNA isolation.

### **Migration assay and invasion assay**

PCa cells ( $3 \times 10^5$ ) in serum-free medium were seeded into FluoroBlock™ Cell Culture insert (BD Falcon). The lower chamber contained conditioned media (CM) with 10% FBS. Migrated cells were labeled with calcein AM [50], and five or more fields were counted for quantification. The same procedure was used for Matrigel-coated invasion chamber (BD Falcon). For TNC neutralization, EC-OSB-CM was incubated with TNC neutralizing antibody BC-24 at 4°C overnight. Anti-cytokeratin antibody AE1/AE3 was used as control. For anti-integrin  $\alpha 5\beta 1$

study, C4-2b-TNC cells were treated with M200 (Volociximab) or IgG for 20 min before assay.

### **Soft agar colony assay**

C4-2B4, C4-2b or PC3-mm2 cells ( $3 \times 10^4$ ) were plated on soft agar as described [51], and incubated in 5% FBS medium containing test proteins or CM for 10 to 14 days. Five or more fields were counted for quantification.

### **Isobaric Tag for Relative and Absolute Quantitation (iTRAQ)**

iTRAQ analysis of CM (10X concentrated) from 2H11 or EC-OSB hybrid cells was performed by Cold Spring Harbor Laboratory's Mass Spectrometry Shared Resource. Samples were digested with trypsin, labeled with 4-plex iTRAQ reagent, and analyzed on an Orbitrap Fusion Lumos mass spectrometer, equipped with a nano-ion spray source coupled to an EASY-nLC 1200 system (Thermo Scientific) as previously described [52].

### **Immunohistochemistry and immunocytochemistry**

Formalin-fixed, paraffin-embedded tissues or methanol-fixed cells were analyzed for TNC as described [53, 54]. Human PCa bone metastasis specimens were obtained from Institutional Tissue Bank at M.D. Anderson Cancer Center through IRB approved protocol.

### **Overexpression of TNC in C4-2b and PC3 cells or overexpression of Hey1 in 2H11 cells**

Human TNC cDNA encoding 1-625 aa was inserted into retroviral vector pBMN-I-GFP to generate pBMN-hTNC-GFP. C4-2b-TNC and PC3-TNC cells were generated by transduction with bicistronic retroviral particles and selected by FACS sorting for GFP. pBMN-I-GFP was used as control. 2H11-oeHey1 cells were generated as previously described [6].

### **Knockdown of transcription factors in prostate cancer or 2H11 cells**

GIPZ lentiviral shRNA (Horizon) was used to knockdown TNC in PC3-mm2 and C4-2b cells. MISSION pLKO.1 lentiviral shRNA (MilliPORE Sigma) was used to knockdown Smad1, Hey1 in 2H11 cells or YAP in C4-2b cells. Cells transduced with empty pGIPZ or pLKO.1 lentiviral vector were used as controls.

### **Intra-prostate injection of prostate cancer cells**

PCa cells ( $1 \times 10^6$ ) were injected into the mouse prostate [55]. Tumor growth was monitored by bioluminescence imaging. DNA was isolated from individual femurs using DNeasy kit. Human-specific *Alu* qPCR was performed to determine the number of tumor cells in each femur as previously described [11].

### **Promoter-luciferase reporter assay**

LightSwitch TNC promoter GoClone expression plasmid was co-transfected with Hey1 expression plasmid or control plasmid into 293T cells using Lipofectamine 2000. TNC promoter-luciferase activity was measured by the LightSwitch Luciferase Assay Kit. 293T cells were transfected with 8xTEAD synthetic YAP/TAZ-responsive promoter-luciferase reporter and treated with BSA or recombinant TNC (5  $\mu\text{g}/\text{mL}$ ) for 48 h to measure YAP1 signaling activity using Dual-luciferase Reporter Assay Kit (Promega).

### **Statistical Analysis**

Data were expressed as the mean  $\pm$  S.D.  $p < 0.05$  by Student's *t*-test was considered statistically significant.

### **Acknowledgements**

This work was supported by grants from the NIH R01CA174798 (S.-H. Lin, L.-Y. Yu-Lee), NIH 5P50CA140388 (C. Logothetis, S.-H. Lin), NIH P30CA16672 Core grant to M.D. Anderson Cancer Center; and Cancer Prevention Research Institute of Texas grants RP150179, RP190252 (S.-H. Lin and L.-Y. Yu-Lee).

### **References**

- 1 Tu S-M, Lin S-H. Clinical aspects of bone metastases in prostate cancer. In: Keller ET, Chung LW (eds). *The Biology of Bone Metastases*. Kluwer Academic Publishers: Boston, MA., 2004, pp 23-46.

- 2 Logothetis C, Lin S-H. Osteoblasts in prostate cancer metastasis to bone. *Nature Reviews Cancer* 2005; 5: 21-28.
- 3 Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY *et al.* BMP4 Promotes Prostate Tumor Growth in Bone through Osteogenesis. *Cancer Res* 2011; 71: 5194-5203.
- 4 Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. *Cancer Res* 2005; 65: 8274-8285.
- 5 Lin SC, Lee YC, Yu G, Cheng CJ, Zhou X, Chu K *et al.* Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. *Developmental cell* 2017; 41: 467-480 e463.
- 6 Yu G, Shen P, Lee YC, Pan J, Song JH, Pan T *et al.* Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4. *iScience* 2021; 24: 102388.
- 7 Midwood KS, Chiquet M, Tucker RP, Orend G. Tenascin-C at a glance. *J Cell Sci* 2016; 129: 4321-4327.
- 8 Li Z, Mathew P, Yang J, Starbuck M-W, Zurita AJ, Liu J *et al.* Androgen receptor-negative human prostate cancer cells induce osteogenesis through FGF9-mediated mechanisms. *J Clin Invest* 2008; 118: 2697-2710. .
- 9 Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH. Clinical impact and functional aspects of tenascin-C expression during glioma progression. *Int J Cancer* 2002; 98: 362-369.
- 10 Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG *et al.* Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. *Nat Med* 2011; 17: 867-874.
- 11 Lee YC, Bilen MA, Yu G, Lin SC, Huang CF, Ortiz A *et al.* Inhibition of cell adhesion by a cadherin-11 antibody thwarts bone metastasis. *Molecular cancer research : MCR* 2013; 11: 1401-1411.
- 12 Grahovac J, Becker D, Wells A. Melanoma cell invasiveness is promoted at least in part by the epidermal growth factor-like repeats of tenascin-C. *J Invest Dermatol* 2013; 133: 210-220.
- 13 Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T *et al.* Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFbetaRIII-p38MAPK-pS249/T252RB Pathway. *Cancer Res* 2018; 78: 2911-2924.

- 14 Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL *et al.* Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. *Cancer Res* 1994; 54: 2577-2581.
- 15 Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF *et al.* Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. *Int J Cancer* 1998; 77: 887-894.
- 16 Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M *et al.* LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. *Prostate* 2000; 44: 91-103.
- 17 Sarkar S, Mirzaei R, Zemp FJ, Wei W, Senger DL, Robbins SM *et al.* Activation of NOTCH Signaling by Tenascin-C Promotes Growth of Human Brain Tumor-Initiating Cells. *Cancer Res* 2017; 77: 3231-3243.
- 18 Jachetti E, Caputo S, Mazzoleni S, Brambillasca CS, Parigi SM, Grioni M *et al.* Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation. *Cancer Res* 2015; 75: 2095-2108.
- 19 Schnapp LM, Hatch N, Ramos DM, Klimanskaya IV, Sheppard D, Pytela R. The human integrin alpha 8 beta 1 functions as a receptor for tenascin, fibronectin, and vitronectin. *J Biol Chem* 1995; 270: 23196-23202.
- 20 San Martin R, Pathak R, Jain A, Jung SY, Hilsenbeck SG, Pina-Barba MC *et al.* Tenascin-C and Integrin alpha9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment. *Cancer Res* 2017; 77: 5977-5988.
- 21 Sun Z, Schwenger A, Rupp T, Murdamoothoo D, Vegliante R, Lefebvre O *et al.* Tenascin-C Promotes Tumor Cell Migration and Metastasis through Integrin alpha9beta1-Mediated YAP Inhibition. *Cancer Res* 2018; 78: 950-961.
- 22 Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, Kozuka Y *et al.* Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. *Am J Pathol* 2011; 178: 754-763.
- 23 Katoh D, Nagaharu K, Shimojo N, Hanamura N, Yamashita M, Kozuka Y *et al.* Binding of alpha v beta 1 and alpha v beta 6 integrins to tenascin-C induces epithelial-mesenchymal transition-like change of breast cancer cells. *Oncogenesis* 2013; 2: e65.
- 24 Jones PL, Crack J, Rabinovitch M. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. *J Cell Biol* 1997; 139: 279-293.

- 25 Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS *et al.* Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. *Cancer Res* 2008; 68: 9996-10003.
- 26 Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. *Nat Rev Gastroenterol Hepatol* 2020; 17: 487-505.
- 27 Heindryckx F, Gerwins P. Targeting the tumor stroma in hepatocellular carcinoma. *World J Hepatol* 2015; 7: 165-176.
- 28 Conklin MW, Keely PJ. Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers. *Cell Adh Migr* 2012; 6: 249-260.
- 29 Riedel A, Shorthouse D, Haas L, Hall BA, Shields J. Tumor-induced stromal reprogramming drives lymph node transformation. *Nat Immunol* 2016; 17: 1118-1127.
- 30 Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y *et al.* Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. *Cell* 2019; 179: 1177-1190 e1113.
- 31 Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. *Neoplasia* 2010; 12: 192-205.
- 32 Nordstrand A, Bovinder Ylitalo E, Thysell E, Jernberg E, Crnalic S, Widmark A *et al.* Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity. *Int J Mol Sci* 2018; 19.
- 33 Fischer A, Klattig J, Kneitz B, Diez H, Maier M, Holtmann B *et al.* Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal hearts. *Molecular and cellular biology* 2005; 25: 8960-8970.
- 34 Miroshnikova YA, Mouw JK, Barnes JM, Pickup MW, Lakins JN, Kim Y *et al.* Tissue mechanics promote IDH1-dependent HIF1alpha-tenascin C feedback to regulate glioblastoma aggression. *Nat Cell Biol* 2016; 18: 1336-1345.
- 35 Qiang L, Wu T, Zhang HW, Lu N, Hu R, Wang YJ *et al.* HIF-1alpha is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. *Cell death and differentiation* 2012; 19: 284-294.
- 36 Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J *et al.* Hypoxia requires notch signaling to maintain the undifferentiated cell state. *Developmental cell* 2005; 9: 617-628.

- 37 Mutvei AP, Landor SK, Fox R, Braune EB, Tsoi YL, Phoon YP *et al.* Notch signaling promotes a HIF2alpha-driven hypoxic response in multiple tumor cell types. *Oncogene* 2018; 37: 6083-6095.
- 38 Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. *Clin Cancer Res* 2002; 8: 2912-2923.
- 39 Ni WD, Yang ZT, Cui CA, Cui Y, Fang LY, Xuan YH. Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer. *Biochemical and biophysical research communications* 2017; 486: 607-612.
- 40 Takada Y, Ye X, Simon S. The integrins. *Genome biology* 2007; 8: 215.
- 41 Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC *et al.* Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. *Cancer Res* 2015; 75: 4949-4959.
- 42 Pan D. The hippo signaling pathway in development and cancer. *Developmental cell* 2010; 19: 491-505.
- 43 Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M *et al.* Role of YAP/TAZ in mechanotransduction. *Nature* 2011; 474: 179-183.
- 44 Totaro A, Panciera T, Piccolo S. YAP/TAZ upstream signals and downstream responses. *Nature Cell Biology* 2018; 20: 888-899.
- 45 Zhu M, Peng R, Liang X, Lan Z, Tang M, Hou P *et al.* P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. *Oncogene* 2021; 40: 6049-6056.
- 46 Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. *Cell* 1986; 47: 131-139.
- 47 Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A *et al.* An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. *Nature genetics* 2008; 40: 499-507.
- 48 Carey WA, Taylor GD, Dean WB, Bristow JD. Tenascin-C deficiency attenuates TGF-ss-mediated fibrosis following murine lung injury. *Am J Physiol Lung Cell Mol Physiol* 2010; 299: L785-793.
- 49 Hong CC, Yu PB. Applications of small molecule BMP inhibitors in physiology and disease. *Cytokine Growth Factor Rev* 2009; 20: 409-418.

- 50 Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye X *et al.* Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. *Cancer Res* 2010 70: 4580-4589. .
- 51 Yu G, Lee YC, Cheng CJ, Wu CF, Song JH, Gallick GE *et al.* RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. *Molecular cancer research : MCR* 2015; 13: 348-357.
- 52 Lee YC, Baath JA, Bastle RM, Bhattacharjee S, Cantoria MJ, Dornan M *et al.* Impact of Detergents on Membrane Protein Complex Isolation. *Journal of proteome research* 2018; 17: 348-358.
- 53 Ye X, Lee YC, Choueiri M, Chu K, Huang CF, Tsai WW *et al.* Aberrant expression of katanin p60 in prostate cancer bone metastasis. *Prostate* 2012; 72: 291-300.
- 54 Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT *et al.* Cadherin-11 promotes the metastasis of prostate cancer cells to bone. *Molecular cancer research : MCR* 2008; 6: 1259-1267.
- 55 Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M *et al.* Targeting constitutively activated beta1 integrins inhibits prostate cancer metastasis. *Molecular cancer research : MCR* 2013; 11: 405-417.

## Figure legends

### **Figure 1. EC-OSB conditioned medium increases the migration, invasion and anchorage-independent growth of PCa cells.**

(A) Morphological change in 2H11 endothelial cells from EC to EC-OSB hybrid cells following BMP4 (100 ng/mL) treatment for 48 h. In this and subsequent experiments, 2H11 cells treated for 48 h with BMP4 are designated as EC-OSB hybrid cells. (B) Alkaline phosphatase activity and osteocalcin mRNA levels in 2H11 cells treated as in (A). (C-E) C4-2B4 or PC3-mm2 PCa cells were treated with conditioned medium (CM) from 2H11 or EC-OSB hybrid cells, or directly with BMP4 alone. The effects of these treatments on (C) migration, (D) invasion, and (E) anchorage-independent growth were measured. P values are from Student's t-test. (F) Graphical summary. BMP4-mediated EC-to-OSB transition generates EC-OSB hybrid cells that secrete factors, which increase the migration, invasion and anchorage-independent growth of PCa cells. BMP4 alone does not elicit these activities in PCa cells.

### **Figure 2. iTRAQ analysis identifies Tenascin C in EC-OSB conditioned medium.**

(A) Flow chart for iTRAQ procedure. (B) The top 15 proteins with the highest fold change in EC-OSB-CM compared to 2H11-CM using iTRAQ. (C) qRT-PCR for mRNA of Tenascin C (TNC), Versican and CTGF in 2H11 cells treated with or without BMP4 for 48 h. P values were by Student's t-test. (D) TNC protein levels in CM or corresponding cells treated as in C. (E) Time course of TNC secretion into CM after BMP4 treatment. CM (10 microliter each) was used in each lane. (F) Immunofluorescence for the expression of TNC in 2H11 cells treated with or without BMP4 for 48 h. Nuclei were stained with DAPI. (G) Upper left, three phases of EC-to-OSB transition in 2H11 cells after treatment with BMP4. Lower left, time course of alkaline phosphatase protein activity in cell lysates. Lower middle, time course of TNC mRNA by qRT-PCR. Lower right, TNC protein levels in CM. Ponceau S, loading control. SF, serum-free.

### **Figure 3. Tenascin C is expressed in tumor-induced osteoblasts in human bone metastasis specimens and Tenascin C neutralizing antibody reduces EC-OSB-CM-mediated migratory activity in PCa cells.**

(A) IHC of TNC in osteogenic tumors. TNC is found in EC-OSB hybrid cells rimming tumor-induced bone in MDA-PCa-118b PDX (left) and human PCa bone metastasis (right). B, bone; T, tumor. Magnification X200. Effects of TNC neutralizing

antibody BC-24 on (B) migratory activity and (C) Anchorage-independent growth of EC-OSB-CM on C4-2B4 and PC3-mm2 cells. EC-OSB-CM were pre-incubated with anti-TNC mAb BC-24 (200 ng/ml) or control anti-AE1/AE3 mAb (200 ng/mL) overnight at 4°C prior to use in migration or anchorage-independent growth assays. P values were by Student's t-test. NS, not significant. (D) Graphical summary. One of the factors secreted by EC-OSB hybrid cells is TNC, which promotes PCa migration, invasion and anchorage-independent growth.

**Figure 4. BMP4 stimulates Tenascin C expression in 2H11 cells through Smad1-Notch/Hey1 pathway.** (A) TNC protein levels in the CM and pSmad1 levels in 2H11 cells treated as indicated. LDN193189, inhibitor of BMP receptor kinase activity. GAPDH, loading control. (B) pSmad1 levels in Smad1 knockdown clones 2H11-shSmad1#1, #3, and #5 treated as indicated. (C) TNC mRNA in cells (upper) and TNC protein in CM (lower) in Smad1 knockdown clones in (B). P values were by Student's t-test. (D) Hey1 mRNA levels in 2H11 cells treated as indicated. (E) Hey1 protein (upper) and mRNA (lower) levels in 2H11-shHey1#2 and #5 clones treated as indicated. (F) TNC mRNA in cells (upper) and TNC protein in CM (lower) in Hey1 knockdown clones in (E). (G) Hey1 mRNA (left) and protein (right) levels in 2H11-oeHey1 cells. Hey1 protein was extracted from cells by immunoprecipitation followed with western blot. (H) TNC mRNA (left) and protein in CM (right) in 2H11-oeHey1 cells. (I) TNC promoter-luciferase construct was co-transfected with Hey1 expression vector in 2H11 cells, and the luciferase reporter activity was measured. (J) Graphical summary. BMP4-stimulates TNC expression through pSmad1-Notch/Hey1 pathway in 2H11 endothelial cells.

**Figure 5. Knockdown of Tenascin C decreases the migration, invasion, anchorage-independent growth of PC3-mm2 cells in vitro and the metastasis of PC3-mm2 cells to bone in vivo.** (A) qRT-PCR for TNC mRNA in PCa cell lines (upper). Western blot of TNC protein in CM from PCa cell lines (lower). (B) qRT-PCR (left) for TNC mRNA in PC3-mm2-shTNC#2, #5, #7 and #8 clones. CMs from PC3-mm2-shTNC clones were analyzed by Western blot (middle) and ELISA (right). (C) Migration, invasion, and anchorage-independent growth of PC3-mm2-shTNC clones in (B). (D) Experimental scheme. PC3-vector, shTNC#2, #5, or #8 cells were injected orthotopically into mouse prostate. After 3 weeks, femurs were dissected and total DNA prepared. Tumor cells that metastasized to bone were determined by human *Alu* sequence


qPCR. (E) Bioluminescence of tumors in the various mouse groups at 3 weeks post-injection. Time course of tumor growth based on bioluminescence is shown. (F) Quantification of tumor cells that have metastasized to bone. Left, average number of tumor cells metastasized from prostate to bone. Right, number of tumor cells detected in individual legs in control mice and PC3-mm2-shTNC#2, shTNC#5, or shTNC#8 injected mice. P values were by Student's t-test.

**Figure 6. Tenascin C increases the migration and anchorage-independent growth of C4-2b cells in vitro and metastasis to lymph nodes in vivo.** C4-2B4 cell migration (A) and anchorage-independent growth in vitro (B) in response to recombinant human TNC (5  $\mu\text{g}/\text{m}$ ), BSA (5  $\mu\text{g}/\text{m}$ ) or media alone. (C) Overexpression of N-terminal domain (1 – 625 aa) of TNC in C4-2b cells by qRT-PCR and western blot. (D-F) Migration, invasion and anchorage-independent growth of cells in (C). (G) C4-2b-vector or C4-2b-TNC cells were injected orthotopically into mouse prostate (upper). Tumor growth was monitored by bioluminescence. When tumors reached certain sizes, they were removed and lymph node metastases were counted (middle). Average number of lymph node metastasis was significantly increased in C4-2b-TNC cells relative to C4-2b-vector control cells (lower). P values were by Student's t-test. (H) Graphical summary. Endothelial cells (EC) undergo EC-to-OSB transition by BMP4. EC-OSB hybrid cells then secrete TNC that increases metastatic potential of PCa cells.


**Figure 7. Tenascin C promotes prostate cancer cell migration through  $\alpha 5\beta 1$ -YAP1 pathway.** (A) Integrin expression in C4-2b cells. (B) Expression of TNC binding integrins in C4-2b-vector and C4-2b-TNC cells. (C) Cell migration in C4-2b-TNC cells incubated with anti- $\alpha 5\beta 1$  integrin neutralizing antibody or control IgG. (D) Nuclear YAP1 protein levels in cells in (B) by Western blot. Lamin A/C, loading control. (E) YAP/TAZ responsive promoter-driven luciferase activity in C4-2b cells incubated with recombinant TNC (rTNC) or BSA control. (F) qRT-PCR for mRNAs of YAP/TAZ target genes in C4-2b-vector or C4-2b-TNC cells. (G) Cell migration in YAP1 knockdown C4-2b-shYAP1-265 or -325 clones. (H) Cell migration in YAP1 knockdown clones in response to recombinant TNC or BSA control. (I) YAP/TAZ target gene expression in C4-2b-TNC cells following incubation with  $\alpha 5\beta 1$  integrin antibody or IgG control. P values were by Student's t-test. (J) Graphical summary. PCa secreted BMP4 induces endothelial cells to undergo EC-to-OSB transition as part of stromal reprogramming, during

which TNC is expressed through a Smad1-Notch/Hey1 signaling pathway. TNC in turn enhances PCa cell migration and invasion through  $\alpha 5\beta 1$  integrin-mediated inhibition of the YAP1 pathway, leading to metastatic progression of PCa in bone.


Figure 1




# Figure 2



# Figure 3



# Figure 4



# Figure 5





Figure 6



**Figure 7**

